Ireland - English - HPRA (Health Products Regulatory Authority)

gedeon richter plc - ethinyloestradiol; levonorgestrel; levonorgestrel; ethinylestradiol; levonorgestrel; ethinylestradiol - coated tablet - . milligram(s) - progestogens and estrogens, sequential preparations; levonorgestrel and ethinylestradiol

United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

gedeon richter (uk) ltd - not applicable

Ireland - English - HPRA (Health Products Regulatory Authority)

medimpex france sa - ethinylestradiol levonorgestrel ethinylestradiol levonorgestrel ethinylestradiol levonorgestrel - coated tablets

Belgium - English - AFMPS (Agence Fédérale des Médicaments et des Produits de Santé)

gedeon richter plc - levonorgestrel 50 µg (pink tablet); ethinylestradiol 30 µg (pink tablet); levonorgestrel 75 µg (white tablet); ethinylestradiol 40 µg (white tablet); levonorgestrel 125 µg (ochre tablet); ethinylestradiol 30 µg (ochre tablet) - coated tablet - ethinylestradiol 30 µg; levonorgestrel 50 µg; levonorgestrel 75 µg; ethinylestradiol 40 µg; levonorgestrel 125 µg; ethinylestradiol 30 µg - levonorgestrel and ethinylestradiol

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, llc - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam 0.25 mg - triazolam is indicated for the short-term treatment of insomnia (generally 7–10 days). use for more than 2–3 weeks requires complete reevaluation of the patient (see warnings). prescriptions for triazolam should be written for short-term use (7–10 days) and it should not be prescribed in quantities exceeding a 1-month supply. triazolam tablets are contraindicated in patients with known hypersensitivity to this drug or other benzodiazepines. benzodiazepines may cause fetal damage when administered during pregnancy. an increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. transplacental distribution has resulted in neonatal cns depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy. triazolam is contraindicated in pregnant women. if there is a likelihood of the patient becoming pregnant while receiving triazolam, she should

United States - English - NLM (National Library of Medicine)

stat rx usa llc - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam 0.25 mg - triazolam is indicated for the short-term treatment of insomnia (generally 7–10 days). use for more than 2–3 weeks requires complete reevaluation of the patient (see warnings). prescriptions for triazolam should be written for short-term use (7–10 days) and it should not be prescribed in quantities exceeding a 1-month supply. triazolam tablets are contraindicated in patients with known hypersensitivity to this drug or other benzodiazepines. benzodiazepines may cause fetal damage when administered during pregnancy. an increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. transplacental distribution has resulted in neonatal cns depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy. triazolam is contraindicated in pregnant women. if there is a likelihood of the patient becoming pregnant while receiving triazolam, she should

United States - English - NLM (National Library of Medicine)

greenstone llc - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam 0.125 mg - triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. triazolam is contraindicated in: pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to psychiatric medications, including triazolam, during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/pregnancyregistry/. risk summary neonates born to mothers using benzodiazepines late in pregnancy have been reported to experience symptoms of sedation and/or neonatal withdrawal [see warnings and precautions (5.10) and clinical considerations] . available data from published observational studies of pregnant women exposed to benzodiazepines do not report a clear association with benzodiazepines and major birth defects (see data ). the background risk of major birth defects and miscarriage for the indic

United States - English - NLM (National Library of Medicine)

pd-rx pharmaceuticals, inc. - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam 0.25 mg - triazolam is indicated for the short-term treatment of insomnia (generally 7 to 10 days) in adults. triazolam is contraindicated in: - patients with known hypersensitivity to triazolam, any of component of triazolam, or other benzodiazepines. reactions consistent with angioedema (involving the tongue, glottis, or larynx), dyspnea, and throat closing have been reported and may be fatal. - concomitant administration of strong cytochrome p450 (cyp 3a) enzyme inhibitors (e.g., ketoconazole, itraconazole, nefazodone, lopinavir, ritonavir) [see warnings and precautions (5.8), drug interactions (7.1)]. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to triazolam during pregnancy. healthcare providers are encouraged to register patients by calling the national pregnancy registry for other psychiatric medications at 1-866-961-2388 or visiting online at https://womensmentalhealth.org/clinical-and-

United States - English - NLM (National Library of Medicine)

unit dose services - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam 0.25 mg - triazolam is indicated for the short-term treatment of insomnia (generally 7–10 days). use for more than 2–3 weeks requires complete reevaluation of the patient (see warnings). prescriptions for triazolam should be written for short-term use (7–10 days) and it should not be prescribed in quantities exceeding a 1-month supply. triazolam tablets are contraindicated in patients with known hypersensitivity to this drug or other benzodiazepines. benzodiazepines may cause fetal damage when administered during pregnancy. an increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. transplacental distribution has resulted in neonatal cns depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy. triazolam is contraindicated in pregnant women. if there is a likelihood of the patient becoming pregnant while receiving triazolam, she should

United States - English - NLM (National Library of Medicine)

aphena pharma solutions - tennessee, inc. - triazolam (unii: 1hm943223r) (triazolam - unii:1hm943223r) - triazolam 0.25 mg - triazolam tablets are indicated for the short-term treatment of insomnia (generally 7 to 10 days). use for more than 2 to 3 weeks requires complete reevaluation of the patient (see warnings). prescriptions for triazolam should be written for short-term use (7 to 10 days) and it should not be prescribed in quantities exceeding a 1-month supply. triazolam tablets are contraindicated in patients with known hypersensitivity to this drug or other benzodiazepines. benzodiazepines may cause fetal damage when administered during pregnancy. an increased risk of congenital malformations associated with the use of diazepam and chlordiazepoxide during the first trimester of pregnancy has been suggested in several studies. transplacental distribution has resulted in neonatal cns depression following the ingestion of therapeutic doses of a benzodiazepine hypnotic during the last weeks of pregnancy. triazolam tablets are contraindicated in pregnant women. if there is a likelihood of the patient becoming pregnant while recei